TOKYO, July 16, 2025 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) introduced today that the drug discovery be taught for Lecanemab (product title: “LEQEMBI®”), a humanized anti-human soluble amyloid B (AB)protofibril monoclonal antibody indicated for early Alzheimer’s illness (early AD*), which change into once co-developed by Eisai and BioArctic AB (Headquarters: Sweden…
Study More
Eisai Awarded “The ninth Bioindustry Award” for Drug Discovery Compare for Anti
You May Also Like
More From Author
Airlines misfortune correct challenges by promoting jet gas as “sustainable”, NGO warns
